A Clinical Study of AK101 in Subjects With Moderate to Severe Plaque Psoriasis

Exclusion Criteria

• •1. Had nonplaque forms of psoriasis (e.g., Guttate, erythrodermic, or pustular).
• •2. Had other active skin diseases or skin infections (e.g., bacterial, fungal or viral infection) that could affect psoriasis evaluation.
• •3. Had Imaging diagnosis of pulmonary infection or fibrosis during the 3 months prior to screening.
• •4. History or evidence of active or latent tuberculosis at screening.
• •5. Serious systemic infections or local infections during the 2 months prior to screening.
• •6. History of cancer, including solid tumors and hematological malignancies (except basal cell and in situ squamous cell carcinomas of the skin that have been excised and resolved).
• •7. Known allergy or hypersensitivity to any biologic therapy at screening that would pose an unacceptable risk to the subject if participating in this study.
• •8. History of alcohol or drug abuse.
• •9. History or known presence of recurrent or chronic infection (e.g., hepatitis B, or C, human immunodeficiency virus \[HIV\], syphilis, TB).
• •10. Had received any DMARDs (e.g., anti-malaria drug, retinoids, interferon, lithium) during 2 weeks prior to screening.
• •11. Had received any physical therapy (e.g., PUVA, ultra-violet therapy, tanning beds) during 2 weeks prior to screening.
• •12. Had received any systemic psoriasis therapy (e.g., glucocorticoid, retinoids, ciclosporin, methotrexate, or tripterygium) during 4 weeks prior to screening.
• •13. Had Enrolled in any other trials during 3 months prior to screening or concurrently enrolled in any other trials.
• •14. Had received previous treatment with any anti-IL-12/IL-23, IL-12, IL-23, IL-17 therapy for the treatment of psoriasis or psoriatic arthritis.
• •15. Had received previous treatment with natalizumab or any other drugs that regulate B cells or T cells (rituximab, abatacept, alemtuzumab) during 12 months prior to screening.
• •16. Had received other biologic therapy (e.g., TNF inhibitor) during 6 months prior to screening.